Incyte Corporation Share Price Today: Live Updates & Key Insights

Incyte Corporation share price today is $91.72, up -2.33%. The stock opened at $92.81 against the previous close of $92.95, with an intraday high of $93.34 and low of $90.34.

Incyte Corporation Share Price Chart

Incyte Corporation

us-stock
To Invest in {{usstockname}}
us-stock

Incyte Corporation Share Price Performance

$91.72 -0.0233(-2.33%) INCY at 23 Mar 2026 01:39 PM Biotechnology
Lowest Today 90.34
Highest Today 93.34
Today’s Open 92.81
Prev. Close 92.95
52 Week High 112.29
52 Week Low 53.56
Day’s Range: Low 90.34 High 93.34
52-Week Range: Low 53.56 High 112.29
1 day return -
1 Week return -2.41
1 month return -10.0
3 month return -9.87
6 month return +7.12
1 year return +44.56
3 year return +25.61
5 year return +11.18
10 year return -

Incyte Corporation Institutional Holdings

Baker Bros Advisors LP 15.45

Vanguard Group Inc 10.01

BlackRock Inc 8.99

Dodge & Cox 6.66

State Street Corp 4.86

Dodge & Cox Stock I 4.52

AQR Capital Management LLC 3.38

Vanguard Total Stock Mkt Idx Inv 2.64

Geode Capital Management, LLC 2.51

Vanguard 500 Index Investor 2.11

Renaissance Technologies Corp 2.00

LSV Asset Management 1.98

Vanguard Small Cap Index 1.90

Arrowstreet Capital Limited Partnership 1.55

Amvescap Plc. 1.54

Morgan Stanley - Brokerage Accounts 1.33

Robeco Institutional Asset Management BV 1.25

Jacobs Levy Equity Management, Inc. 1.15

Acadian Asset Management LLC 1.13

iShares Core S&P 500 ETF 1.06

Vanguard Small Cap Growth Index Inv 1.06

Fidelity 500 Index 1.05

State Street® SPDR® S&P 500® ETF 0.98

Invesco S&P 500® Equal Weight ETF 0.90

Dimensional Fund Advisors, Inc. 0.90

Los Angeles Capital Management LLC 0.88

Charles Schwab Investment Management Inc 0.87

Northern Trust Corp 0.87

Pacer Advisors, INC. 0.86

iShares Biotechnology ETF 0.73

BB Biotech AG Ord 0.72

iShares MSCI USA Min Vol Factor ETF 0.65

VictoryShares Free Cash Flow ETF 0.64

State Street®HlthCrSelSectSPDR®ETF 0.61

Dodge & Cox Balanced Composite 0.60

Dodge & Cox Balanced I 0.60

State Street® SPDR® S&P® Biotech ETF 0.51

Vanguard Institutional Index I 0.47

State St S&P 500® Indx SL Cl III 0.44

First Trust NYSE Arca Biotech ETF 0.38

Incyte Corporation Market Status

Strong Buy: 8

Buy: 3

Hold: 15

Sell: 1

Strong Sell: 0

Incyte Corporation Fundamentals

Market Cap 18066.53 M

PB Ratio 3.4962

PE Ratio 14.1622

Enterprise Value 14526.34 M

Total Assets 6957.97 M

Volume 4388758

Incyte Corporation Company Financials

Annual Revenue FY25:5141242000 5141.2M, FY24:4241217000 4241.2M, FY23:3609008000 3609.0M, FY22:3394635000 3394.6M, FY21:2986267000 2986.3M

Annual Profit FY25:4702526000 4702.5M, FY24:3929149000 3929.1M, FY23:3364608000 3364.6M, FY22:3187638000 3187.6M, FY21:2835276000 2835.3M

Annual Net worth FY25:1286650000 1286.7M, FY24:32615000 32.6M, FY23:424981000 425.0M, FY22:340660000 340.7M, FY21:948581000 948.6M

Quarterly Revenue Q4/2025:1506835000 1506.8M, Q3/2025:1365980000 1366.0M, Q2/2025:1215529000 1215.5M, Q1/2025:1052897999 1052.9M, Q4/2024:1178698000 1178.7M

Quarterly Profit Q4/2025:1369478000 1369.5M, Q3/2025:1266980000 1267.0M, Q2/2025:1119844000 1119.8M, Q1/2025:963348000 963.3M, Q4/2024:1090198000 1090.2M

Quarterly Net worth Q4/2025:299279000 299.3M, Q3/2025:424169000 424.2M, Q2/2025:404999000 405.0M, Q1/2025:158203000 158.2M, Q4/2024:201212000 201.2M

About Incyte Corporation & investment objective

Company Information Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics in the United States, Europe, Canada, and Japan. The company offers JAKAFI for the treatment of myelofibrosis (MF), polycythemia vera, and steroid-refractory acute graft-versus-host disease; ICLUSIG, a kinase inhibitor to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; MONJUVI/ MINJUVI for the treatment of diffuse large B-cell lymphoma and Follicular Lymphoma; NIKTIMVO for the treatment of chronic graft-versus-host disease. It also provides INCA033989 for the treatment of essential thrombocythemia and MF; INCA035784 for the treatment of anti-mutant calreticulin and myeloproliferative neoplasms (MPNs); INCB160058 for the treatment of MPNs; PEMAZYRE, a selective fibroblast growth factor receptor kinase inhibitor for the treatment of unresectable biliary tract cancer, metastatic cholangiocarcinoma, and myeloid/lymphoid neoplasms; ZYNYZ to treat adults with metastatic or recurrent locally advanced Merkel cell carcinoma. The company's clinical stage products include INCB123667 for ovarian cancer; INCB161734 for solid tumors; INCA33890 for cancers; Ruxolitinib cream for atopic dermatitis, hidradenitis suppurativa (HS), and prurigo nodularis; Povorcitinib for HS, nonsegmental vitiligo, prurigo nodularis, and asthma; and INCB00928 for the treatment of fibrodysplasia ossificans progressive. It has collaboration and license agreement with Novartis, Lilly, and Syndax. The company sells its products to specialty and retail pharmacies, hospital pharmacies, and distributors. The company was formerly known as Incyte Genomics Inc and changed its name to Incyte Corporation in March 2003. Incyte Corporation was incorporated in 1991 and is headquartered in Wilmington, Delaware.

Organisation Biotechnology

Employees 2844

Industry Biotechnology

CEO Mr. William J. Meury

Trading and brokerage services provided by

Technology Services provided by Motilal Oswal Financial Services:

Disclaimer: These services are not for exchange traded products. The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Motilal Oswal Financial Services acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*

Take your next step

Talk to our investment advisor for stock recommendations
Left
Get expert assistance for portfolio management
Right

Incyte Corporation FAQs

What is the share price of Incyte Corporation today?

The current share price of Incyte Corporation is $91.72.

Can I buy Incyte Corporation shares in India?

Yes, Indian investors can buy Incyte Corporation shares by opening an international trading and demat account with Motilal Oswal.

How to buy Incyte Corporation shares in India?

You can easily invest in Incyte Corporation shares from India by:

Can I buy fractional shares of Incyte Corporation?

Yes, many platforms allow you to buy fractional shares starting from as low as $1.

What is the market capitalization value of Incyte Corporation?

Incyte Corporation has a market cap of $18066.53 M.

In which sector does Incyte Corporation belong?

Incyte Corporation operates in the Biotechnology sector.

What documents are required to invest in Incyte Corporation stocks?

To invest, you typically need:

What is the PE and PB ratio of Incyte Corporation?

The PE ratio of Incyte Corporation is 14.16 and the PB ratio is 3.50.